Compare CLBK & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLBK | GLPG |
|---|---|---|
| Founded | 1927 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2017 | N/A |
| Metric | CLBK | GLPG |
|---|---|---|
| Price | $20.70 | $27.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $17.00 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 368.6K | 263.2K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 563.64 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $11.43 | N/A |
| P/E Ratio | $159.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.66 | $26.62 |
| 52 Week High | $21.20 | $37.78 |
| Indicator | CLBK | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 64.26 | 36.53 |
| Support Level | $19.69 | N/A |
| Resistance Level | N/A | $34.04 |
| Average True Range (ATR) | 0.39 | 0.56 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 76.08 | 25.33 |
Columbia Financial Inc is a federally chartered savings bank that serves the financial needs of depositors and the local community as a customer service-focused institution. The company offers traditional financial services to businesses and consumers in its market areas. It attracts deposits from the general public and uses those funds to originate various loans, including multifamily and commercial real estate loans, commercial business loans, one-to-four family real estate loans, construction loans, home equity loans and advances, and other consumer loans. The company also offers title insurance through its wholly owned subsidiary and provides a broad range of insurance products, including personal and business lines of insurance, mainly to customers and New Jersey residents.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.